Since our studies indicated that 2HF could be useful in the therapy of melanoma when used alone and in combination with sunitinib or PARP1 inhibitors, we considered whether it could be used as systemic therapy as an adjunct to these drugs. This evidence concerns the gene PARP1 and melanoma.